Jian Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jian Chen has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Linhao Xu
Department of Cardiology, Affiliated Hangzhou First People’S Hospital, Westlake University School of Medicine, Zhejiang, China
4 shared publications Yanli Bi
Department of Clinical Laboratorial Examination, Air Force Hangzhou Special Service Recuperation Center Sanatorium Area 3, Hangzhou, Zhejiang 310013, China
4 shared publicationsSenwen Zheng
School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China
3 shared publications- Yizhou Xu
Department of Cardiology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 shared publications Yuxin Jiang
School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China
3 shared publicationsLingjie Zhou
School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, China
2 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 28
Pharmacological intervention of Chinese medicine via regulating ferroptosis in gastric cancer
Gastric cancer (GC) is the second most frequently diagnosed malignancy, as well as the second most common cause of cancer-related deaths in China. Drug resistance is a major factor that limits the efficacy of GC chemotherapy. Given the increased resistance of GC cells to ferroptosis, activating the ferroptotic pathways has emerged as a promising therapeutic strategy against GC. This review summarizes the pathways involved in ferroptosis resistance in GC cells and the mechanisms underlying the therapeutic effects of herbal formulae and their bioactive compounds, with particular emphasis on ferroptosis. Multiple signaling pathways are implicated in regulating ferroptosis in GC cells, including the Wnt/β-catenin, PI3K/AKT/mTOR, TGF-β1/Smad, NF-κB, and Hippo pathways. According to previous clinical trials, traditional Chinese medicine (TCM) formulations can prolong the survival or increase survival chances in patients with GC, and reduce adverse reactions, thereby improving the quality of life. Finally, preclinical studies have shown TCMs and their bioactive compounds can ameliorate GC progression by triggering ferroptosis. Despite these beneficial effects on patients with GC, the underlying molecular mechanisms of TCM in GC have not been fully elucidated yet, and there are also some crucial shortcomings in the current studies. Therefore, further clinical trials and experimental studies are required to deepen our understanding of the mechanisms for activating ferroptosis in GC cells through TCM. Graphical Abstract
- 12 January 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 28
Open AccessPharmacological intervention of Chinese medicine via regulating ferroptosis in gastric cancer
Gastric cancer (GC) is the second most frequently diagnosed malignancy, as well as the second most common cause of cancer-related deaths in China. Drug resistance is a major factor that limits the efficacy of GC chemotherapy. Given the increased resistance of GC cells to ferroptosis, activating the ferroptotic pathways has emerged as a promising therapeutic strategy against GC. This review summarizes the pathways involved in ferroptosis resistance in GC cells and the mechanisms underlying the therapeutic effects of herbal formulae and their bioactive compounds, with particular emphasis on ferroptosis. Multiple signaling pathways are implicated in regulating ferroptosis in GC cells, including the Wnt/β-catenin, PI3K/AKT/mTOR, TGF-β1/Smad, NF-κB, and Hippo pathways. According to previous clinical trials, traditional Chinese medicine (TCM) formulations can prolong the survival or increase survival chances in patients with GC, and reduce adverse reactions, thereby improving the quality of life. Finally, preclinical studies have shown TCMs and their bioactive compounds can ameliorate GC progression by triggering ferroptosis. Despite these beneficial effects on patients with GC, the underlying molecular mechanisms of TCM in GC have not been fully elucidated yet, and there are also some crucial shortcomings in the current studies. Therefore, further clinical trials and experimental studies are required to deepen our understanding of the mechanisms for activating ferroptosis in GC cells through TCM. Graphical Abstract
- 15 August 2024
- Published by Elsevier in Cellular Signalling
- Vol. 122, 111348
Activation of SIRT3 by Tanshinone IIA ameliorates renal fibrosis by suppressing the TGF-β/TSP-1 pathway and attenuating oxidative stress
- 15 August 2024
- Published by Elsevier in Cellular Signalling
- Vol. 122, 111348
Activation of SIRT3 by Tanshinone IIA ameliorates renal fibrosis by suppressing the TGF-β/TSP-1 pathway and attenuating oxidative stress
- Open Access
- 6 May 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116684
Suppression of PERK/eIF2α/CHOP pathway enhances oridonin-induced apoptosis by inhibiting autophagy in Small-Cell lung cancer cells
- 6 May 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116684
Open AccessSuppression of PERK/eIF2α/CHOP pathway enhances oridonin-induced apoptosis by inhibiting autophagy in Small-Cell lung cancer cells
- Open Access
- 31 January 2024
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 24 (1) , 1-11
Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells
Background: Small cell lung cancer (SCLC) is the most malignant lung cancer type. Due to the high rates of metastasis and drug resistance, effective therapeutic strategies remain lacking. Tanshinone IIA (Tan IIA) has been reported to exhibit anti-tumor activity. Therefore, this study investigated the ability and underlying mechanism of Tan IIA to inhibit the metastasis and proliferation of SCLC. Methods: H1688 and H446 cells were treated in vitro with Tan IIA (0, 1, 2 and 4 µM) or LY294002 (10 µM) for 24, 48, 72 h. H1688 and H446 cell migration was evaluated in wound healing and transwell migration assays. RNA-sequencing helped assess gene expression. BALB/c nude mice were injected with H1688 cells and treated with the Tan IIA group (10 mg/kg/day) or a control. Expression of E-cadherin, vimentin and PI3K/Akt signaling pathway proteins in tumors and H1688 was investigated by immunohistochemical analysis and western blot. Results: Tan IIA inhibited H1688 and H446 cell proliferation without inducing apoptosis and suppressed H1688 and H446 cell migration. E-cadherin expression was increased, while vimentin expression was reduced after administration of Tan IIA. RNA-sequencing revealed that some genes related with the PI3K/Akt signaling pathway were altered using Tan IIA treatment. Furthermore, western blot helped detect PI3K and p-Akt expression was also reduced by Tan IIA treatment. Tan IIA inhibited tumor growth in vivo. Moreover, Tan IIA increased tumoral expression of E-cadherin accompanied by PI3K and p-Akt downregulation. Conclusion: Tan IIA suppresses SCLC proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway, thereby highlighting the potential of Tan IIA as a new and relatively safe drug candidate to treat SCLC.
- 31 January 2024
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 24 (1) , 1-11
Open AccessTanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells
Background: Small cell lung cancer (SCLC) is the most malignant lung cancer type. Due to the high rates of metastasis and drug resistance, effective therapeutic strategies remain lacking. Tanshinone IIA (Tan IIA) has been reported to exhibit anti-tumor activity. Therefore, this study investigated the ability and underlying mechanism of Tan IIA to inhibit the metastasis and proliferation of SCLC. Methods: H1688 and H446 cells were treated in vitro with Tan IIA (0, 1, 2 and 4 µM) or LY294002 (10 µM) for 24, 48, 72 h. H1688 and H446 cell migration was evaluated in wound healing and transwell migration assays. RNA-sequencing helped assess gene expression. BALB/c nude mice were injected with H1688 cells and treated with the Tan IIA group (10 mg/kg/day) or a control. Expression of E-cadherin, vimentin and PI3K/Akt signaling pathway proteins in tumors and H1688 was investigated by immunohistochemical analysis and western blot. Results: Tan IIA inhibited H1688 and H446 cell proliferation without inducing apoptosis and suppressed H1688 and H446 cell migration. E-cadherin expression was increased, while vimentin expression was reduced after administration of Tan IIA. RNA-sequencing revealed that some genes related with the PI3K/Akt signaling pathway were altered using Tan IIA treatment. Furthermore, western blot helped detect PI3K and p-Akt expression was also reduced by Tan IIA treatment. Tan IIA inhibited tumor growth in vivo. Moreover, Tan IIA increased tumoral expression of E-cadherin accompanied by PI3K and p-Akt downregulation. Conclusion: Tan IIA suppresses SCLC proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway, thereby highlighting the potential of Tan IIA as a new and relatively safe drug candidate to treat SCLC.
- Open Access
- 23 January 2023
- Published by Springer Nature in Research Square
Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells
Background Small cell lung cancer (SCLC) is the most malignant type of lung cancer. Due to the high rates of metastasis and drug resistance, effective therapeutic strategies are lacking. Tanshinone IIA (Tan IIA) has been reported to exhibit anti-tumor activity. Therefore, in this study, we investigated the ability of Tan IIA to inhibit the metastasis and proliferation of SCLC and the underlying mechanism. Methods H1688 cells were treated in vitro with Tan IIA (0, 1, 2 and 4 µM) and LY294002 (10 µM) for 24, 48, 72 hours. H1688 cell migration was evaluated in wound healing and transwell migration assays. Expression of genes was evaluated by RNA-sequencing. BALB/c nude mice were injected with H1688 cells and treated with Tan IIA group (10 mg/kg/day) or a control. Expression of E-cadherin, vimentin and PI3K/Akt signaling pathway proteins in tumors and in H1688 was investigated by immunohistochemical analysis and western blot, respectively. Results Tan IIA inhibited H1688 cell proliferation without inducing apoptosis and suppressed H1688 cell migration. E-cadherin expression was increased, while vimentin expression was reduced after administration of Tan IIA. The analysis of RNA-sequencing showed that some genes associated with PI3K/Akt signaling pathway were altered by Tan IIA treatment. Furthermore, western blot detected the expression of PI3K and p-Akt was also reduced by Tan IIA treatment. In vivo, Tan IIA inhibited tumor growth. Furthermore, Tan IIA increased tumoral expression of E-cadherin accompanied by downregulation of PI3K and p-Akt. Conclusion Tan IIA suppresses SCLC proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway, thus indicating the potential of Tan IIA as a new and relatively safe drug candidate for the treatment of SCLC.
- 23 January 2023
- Published by Springer Nature in Research Square
Open AccessTanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells
Background Small cell lung cancer (SCLC) is the most malignant type of lung cancer. Due to the high rates of metastasis and drug resistance, effective therapeutic strategies are lacking. Tanshinone IIA (Tan IIA) has been reported to exhibit anti-tumor activity. Therefore, in this study, we investigated the ability of Tan IIA to inhibit the metastasis and proliferation of SCLC and the underlying mechanism. Methods H1688 cells were treated in vitro with Tan IIA (0, 1, 2 and 4 µM) and LY294002 (10 µM) for 24, 48, 72 hours. H1688 cell migration was evaluated in wound healing and transwell migration assays. Expression of genes was evaluated by RNA-sequencing. BALB/c nude mice were injected with H1688 cells and treated with Tan IIA group (10 mg/kg/day) or a control. Expression of E-cadherin, vimentin and PI3K/Akt signaling pathway proteins in tumors and in H1688 was investigated by immunohistochemical analysis and western blot, respectively. Results Tan IIA inhibited H1688 cell proliferation without inducing apoptosis and suppressed H1688 cell migration. E-cadherin expression was increased, while vimentin expression was reduced after administration of Tan IIA. The analysis of RNA-sequencing showed that some genes associated with PI3K/Akt signaling pathway were altered by Tan IIA treatment. Furthermore, western blot detected the expression of PI3K and p-Akt was also reduced by Tan IIA treatment. In vivo, Tan IIA inhibited tumor growth. Furthermore, Tan IIA increased tumoral expression of E-cadherin accompanied by downregulation of PI3K and p-Akt. Conclusion Tan IIA suppresses SCLC proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway, thus indicating the potential of Tan IIA as a new and relatively safe drug candidate for the treatment of SCLC.
- Open Access
- 8 October 2021
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 21 (1) , 1-12
Tanshinone IIA attenuates renal injury during hypothermic preservation via the MEK/ERK1/2/GSK-3β pathway
Oxidative stress-induced injury during hypothermic preservation is a universal problem that delays graft function and decrease the success of organ transplantation. Tanshinone IIA (Tan IIA) was reported to exhibit a variety of biochemical activities, including protection against oxidative stress. Therefore, the specific molecular pathway by which Tan IIA protects renal tissues during preservation was investigated in this study. In vivo study, Sprague-Dawley (SD) rats were divided into twelve groups and the kidneys were isolated and preserved in different solutions for 0, 24 or 48 h, respectively: control group (Celsior solution) and Tan II groups (Celsior solution containing 10, 50,100 μM). In vitro study, primary renal cell from SD rats was cultured which was treated H2O2 (800 μM) for 6 h to mimic oxidative stress injury. Four groups were finally divided: control group; H2O2 group; H2O2 + Tan IIA group; H2O2 + Tan IIA + G15 group. In present study, we demonstrate data indicating that a significant increase in the superoxide dismutase (SOD) activity and a decrease in the reactive oxygen species (ROS) content were observed in the kidneys and renal cells preserved with Tan IIA compared with those preserved with the Celsior solution alone after 24 h and 48 h of hypothermic preservation (P < 0.01). The expression of phosphorylated mitogen-activated protein kinase kinase (MEK), phosphorylated extracellular signal-regulated protein kinases 1/2 (ERK1/2), phosphorylated glycogen synthase kinase-3β (GSK-3β) and cleaved caspase-3 was lower in the kidneys and renal cells preserved with Tan IIA than in those preserved with the Celsior solution alone after 24 h and 48 h of hypothermic preservation (P < 0.01). The mitochondrial morphology was rescued and adenosine triphophate (ATP) production and mitochondrial membrane potential were increased in the Tan IIA groups. Finally, Tan IIA also decreased cell apoptosis. It suggests that the supplementation of the standard Celsior solution with Tan IIA may significantly improve long-term kidney preservation. Tan IIA attenuated oxidative stress injury and decreased apoptosis levels via activation of the MEK/ERK1/2/GSK-3β signaling pathway during kidney hypothermic preservation.
- 8 October 2021
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 21 (1) , 1-12
Open AccessTanshinone IIA attenuates renal injury during hypothermic preservation via the MEK/ERK1/2/GSK-3β pathway
Oxidative stress-induced injury during hypothermic preservation is a universal problem that delays graft function and decrease the success of organ transplantation. Tanshinone IIA (Tan IIA) was reported to exhibit a variety of biochemical activities, including protection against oxidative stress. Therefore, the specific molecular pathway by which Tan IIA protects renal tissues during preservation was investigated in this study. In vivo study, Sprague-Dawley (SD) rats were divided into twelve groups and the kidneys were isolated and preserved in different solutions for 0, 24 or 48 h, respectively: control group (Celsior solution) and Tan II groups (Celsior solution containing 10, 50,100 μM). In vitro study, primary renal cell from SD rats was cultured which was treated H2O2 (800 μM) for 6 h to mimic oxidative stress injury. Four groups were finally divided: control group; H2O2 group; H2O2 + Tan IIA group; H2O2 + Tan IIA + G15 group. In present study, we demonstrate data indicating that a significant increase in the superoxide dismutase (SOD) activity and a decrease in the reactive oxygen species (ROS) content were observed in the kidneys and renal cells preserved with Tan IIA compared with those preserved with the Celsior solution alone after 24 h and 48 h of hypothermic preservation (P < 0.01). The expression of phosphorylated mitogen-activated protein kinase kinase (MEK), phosphorylated extracellular signal-regulated protein kinases 1/2 (ERK1/2), phosphorylated glycogen synthase kinase-3β (GSK-3β) and cleaved caspase-3 was lower in the kidneys and renal cells preserved with Tan IIA than in those preserved with the Celsior solution alone after 24 h and 48 h of hypothermic preservation (P < 0.01). The mitochondrial morphology was rescued and adenosine triphophate (ATP) production and mitochondrial membrane potential were increased in the Tan IIA groups. Finally, Tan IIA also decreased cell apoptosis. It suggests that the supplementation of the standard Celsior solution with Tan IIA may significantly improve long-term kidney preservation. Tan IIA attenuated oxidative stress injury and decreased apoptosis levels via activation of the MEK/ERK1/2/GSK-3β signaling pathway during kidney hypothermic preservation.
- Open Access
- 21 August 2021
- Published by Wiley in Neural Plasticity
- Vol. 2021, 1-14
Suppression of CHOP Reduces Neuronal Apoptosis and Rescues Cognitive Impairment Induced by Intermittent Hypoxia by Inhibiting Bax and Bak Activation
Our previous study showed that growth arrest- and DNA damage-inducible gene 153 (GAD153/CHOP) plays an important role in intermittent hypoxia- (IH-) induced apoptosis and impaired synaptic plasticity. This study is aimed at determining which signaling pathway is activated to induce CHOP and the role of this protein in mitochondria-dependent apoptosis induced by IH. In the in vivo study, mice were placed in IH chambers for 8h daily over a period of 2 weeks; the IH chambers had oxygen (O2) concentrations that oscillated between 10 and 21, cycling every 90s. In the in vitro study, PC12 cells were exposed to 21 O2 (normoxia) or 8 IH cycles (25min at 21 O2 and 35min at 0.1 O2 for each cycle). After 2 weeks of IH treatment, we observed that the expression levels of phosphorylated protein kinase-like endoplasmic reticulum kinase (p-PERK), activating transcription factor 4 (ATF-4) and phosphorylated eukaryotic initiation factor 2 alpha (p-elf2α), were increased, but the levels of activating transcription factor 6 (ATF-6) and inositol-requiring enzyme 1 (IRE-1) were not increased. GSK2606414, a specific chemical inhibitor of the PERK pathway, reduced the expression of p-PERK, ATF-4, p-elf2α, and CHOP and rescued ER structure. In addition, Bax and Bak accumulated in the mitochondria after IH treatment, which induced cytochrome c release and initiated apoptosis. These effects were prevented by GSK2606414 and CHOP shRNA. Finally, the impaired long-term potentiation and long-term spatial memory in the IH group were rescued by GSK2606414. Together, the data from the in vitro and in vivo experiments indicate that IH-induced apoptosis and impaired synaptic plasticity were mediated by the PERK-ATF-4-CHOP pathway. Suppressing PERK-ATF-4-CHOP signaling pathway attenuated mitochondria-dependent apoptosis by reducing the expression of Bax and Bak in mitochondria, which may serve as novel adjunct therapeutic strategy for ameliorating obstructive sleep apnea- (OSA-) induced neurocognitive impairment.
- 21 August 2021
- Published by Wiley in Neural Plasticity
- Vol. 2021, 1-14
Open AccessSuppression of CHOP Reduces Neuronal Apoptosis and Rescues Cognitive Impairment Induced by Intermittent Hypoxia by Inhibiting Bax and Bak Activation
Our previous study showed that growth arrest- and DNA damage-inducible gene 153 (GAD153/CHOP) plays an important role in intermittent hypoxia- (IH-) induced apoptosis and impaired synaptic plasticity. This study is aimed at determining which signaling pathway is activated to induce CHOP and the role of this protein in mitochondria-dependent apoptosis induced by IH. In the in vivo study, mice were placed in IH chambers for 8h daily over a period of 2 weeks; the IH chambers had oxygen (O2) concentrations that oscillated between 10 and 21, cycling every 90s. In the in vitro study, PC12 cells were exposed to 21 O2 (normoxia) or 8 IH cycles (25min at 21 O2 and 35min at 0.1 O2 for each cycle). After 2 weeks of IH treatment, we observed that the expression levels of phosphorylated protein kinase-like endoplasmic reticulum kinase (p-PERK), activating transcription factor 4 (ATF-4) and phosphorylated eukaryotic initiation factor 2 alpha (p-elf2α), were increased, but the levels of activating transcription factor 6 (ATF-6) and inositol-requiring enzyme 1 (IRE-1) were not increased. GSK2606414, a specific chemical inhibitor of the PERK pathway, reduced the expression of p-PERK, ATF-4, p-elf2α, and CHOP and rescued ER structure. In addition, Bax and Bak accumulated in the mitochondria after IH treatment, which induced cytochrome c release and initiated apoptosis. These effects were prevented by GSK2606414 and CHOP shRNA. Finally, the impaired long-term potentiation and long-term spatial memory in the IH group were rescued by GSK2606414. Together, the data from the in vitro and in vivo experiments indicate that IH-induced apoptosis and impaired synaptic plasticity were mediated by the PERK-ATF-4-CHOP pathway. Suppressing PERK-ATF-4-CHOP signaling pathway attenuated mitochondria-dependent apoptosis by reducing the expression of Bax and Bak in mitochondria, which may serve as novel adjunct therapeutic strategy for ameliorating obstructive sleep apnea- (OSA-) induced neurocognitive impairment.
- Open Access
- 25 August 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 20 (5) , 1
The role of reactive oxygen species in cognitive impairment associated with sleep apnea
Obstructive sleep apnea (OSA), a common breathing and sleeping disorder, is associated with a broad range of neurocognitive difficulties. Intermittent hypoxia (IH), one major characteristic of OSA, has been shown to impair learning and memory due to increased levels of reactive oxygen species (ROS). Under normal conditions, ROS are produced in low concentrations and act as signaling molecules in different processes. However, IH treatment leads to elevated ROS production via multiple pathways, including mitochondrial electron transport chain dysfunction and in particular complex I dysfunction, and induces oxidative tissue damage. Moreover, elevated ROS results in the accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER) and increased activity of peroxisomes, such as NADPH oxidase, xanthine oxidase and phospholipase A2. Furthermore, oxidative tissue damage has been found in regions of the brains of patients with OSA, including the cortex and hippocampus, which are associated with memory and executive function. Furthermore, increased ROS levels in these regions of the brain induce damage via inflammation, apoptosis, ER stress and neuronal activity disturbance. The present review focuses on the mechanism of excessive ROS production in an OSA model and the relationship between ROS and cognitive impairment.
- 25 August 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 20 (5) , 1
Open AccessThe role of reactive oxygen species in cognitive impairment associated with sleep apnea
Obstructive sleep apnea (OSA), a common breathing and sleeping disorder, is associated with a broad range of neurocognitive difficulties. Intermittent hypoxia (IH), one major characteristic of OSA, has been shown to impair learning and memory due to increased levels of reactive oxygen species (ROS). Under normal conditions, ROS are produced in low concentrations and act as signaling molecules in different processes. However, IH treatment leads to elevated ROS production via multiple pathways, including mitochondrial electron transport chain dysfunction and in particular complex I dysfunction, and induces oxidative tissue damage. Moreover, elevated ROS results in the accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER) and increased activity of peroxisomes, such as NADPH oxidase, xanthine oxidase and phospholipase A2. Furthermore, oxidative tissue damage has been found in regions of the brains of patients with OSA, including the cortex and hippocampus, which are associated with memory and executive function. Furthermore, increased ROS levels in these regions of the brain induce damage via inflammation, apoptosis, ER stress and neuronal activity disturbance. The present review focuses on the mechanism of excessive ROS production in an OSA model and the relationship between ROS and cognitive impairment.
- Open Access
- 12 June 2020
- Published by Wiley in Journal of Diabetes Research
- Vol. 2020, 1-14
Thrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications
Fibrosis accompanies most common pathophysiological features of diabetes complications in different organs. It is characterized by an excessive accumulation of extracellular matrix (ECM) components, the response to which contributes to inevitable organ injury. The extracellular protein thrombospondin-1 (TSP-1), a kind of extracellular glycoprotein, is upregulated by the increased activity of some transcription factors and results in fibrosis by activating multiple pathways in diabetes. The results of studies from our team and other colleagues indicate that TSP-1 is associated with the pathological process leading to diabetic complications and is considered to be the most important factor in fibrosis. This review summarizes the molecular mechanism of increased TSP-1 induced by hyperglycemia and the role of TSP-1 in fibrosis during the development of diabetes complications.
- 12 June 2020
- Published by Wiley in Journal of Diabetes Research
- Vol. 2020, 1-14
Open AccessThrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications
Fibrosis accompanies most common pathophysiological features of diabetes complications in different organs. It is characterized by an excessive accumulation of extracellular matrix (ECM) components, the response to which contributes to inevitable organ injury. The extracellular protein thrombospondin-1 (TSP-1), a kind of extracellular glycoprotein, is upregulated by the increased activity of some transcription factors and results in fibrosis by activating multiple pathways in diabetes. The results of studies from our team and other colleagues indicate that TSP-1 is associated with the pathological process leading to diabetic complications and is considered to be the most important factor in fibrosis. This review summarizes the molecular mechanism of increased TSP-1 induced by hyperglycemia and the role of TSP-1 in fibrosis during the development of diabetes complications.
- Open Access
- 13 March 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (8) , 4480-4493
Oridonin inhibits the migration and epithelial‐to‐mesenchymal transition of small cell lung cancer cells by suppressing FAK‐ERK1/2 signalling pathway
Small cell lung cancer (SCLC) is a severe malignant with high morbidity; however, few effective and secure therapeutic strategy is used in current clinical practice. Oridonin is a small molecule from the traditional Chinese herb Rabdosia rubescens. This study mainly aimed to investigate the role of oridonin on inhibiting the process of H1688, a kind of small cell lung cancer cells from human. Oridonin could suppress H1688 cell proliferation and induce their apoptosis in a high dosage treatment (20 μmol/L). Meanwhile, cell migration was suppressed by oridonin (5 and 10 μmol/L) that did not affect cell proliferation and apoptosis. The expression level of E‐cadherin was significantly increased, and the expression of vimentin, snail and slug was reduced after administration of oridonin. These expression changes were associated with the suppressed integrin β1, phosphorylation of focal adhesion kinase (FAK) and ERK1/2. In addition, oridonin (5 and 10 mg/kg) inhibited tumour growth in a nude mouse model; however, HE staining revealed a certain degree of cytotoxicity in hepatic tissue after treatment oridonin (10 mg/kg). Furthermore, the concentration of alanine aminotransferase (ALP) was significantly increased and lactate dehydrogenase (LDH) was reduced after oridonin treatment (10 mg/kg). Immunohistochemical analysis further revealed that oridonin increased E‐cadherin expression and reduced vimentin and phospho‐FAK levels in vivo. These findings indicated that oridonin can inhibit the migration and epithelial‐to‐mesenchymal transition (EMT) of SCLC cells by suppressing the FAK‐ERK1/2 signalling pathway. Thus, oridonin may be a new drug candidate to offer an effect of anti‐SCLC with relative safety.
- 13 March 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (8) , 4480-4493
Open AccessOridonin inhibits the migration and epithelial‐to‐mesenchymal transition of small cell lung cancer cells by suppressing FAK‐ERK1/2 signalling pathway
Small cell lung cancer (SCLC) is a severe malignant with high morbidity; however, few effective and secure therapeutic strategy is used in current clinical practice. Oridonin is a small molecule from the traditional Chinese herb Rabdosia rubescens. This study mainly aimed to investigate the role of oridonin on inhibiting the process of H1688, a kind of small cell lung cancer cells from human. Oridonin could suppress H1688 cell proliferation and induce their apoptosis in a high dosage treatment (20 μmol/L). Meanwhile, cell migration was suppressed by oridonin (5 and 10 μmol/L) that did not affect cell proliferation and apoptosis. The expression level of E‐cadherin was significantly increased, and the expression of vimentin, snail and slug was reduced after administration of oridonin. These expression changes were associated with the suppressed integrin β1, phosphorylation of focal adhesion kinase (FAK) and ERK1/2. In addition, oridonin (5 and 10 mg/kg) inhibited tumour growth in a nude mouse model; however, HE staining revealed a certain degree of cytotoxicity in hepatic tissue after treatment oridonin (10 mg/kg). Furthermore, the concentration of alanine aminotransferase (ALP) was significantly increased and lactate dehydrogenase (LDH) was reduced after oridonin treatment (10 mg/kg). Immunohistochemical analysis further revealed that oridonin increased E‐cadherin expression and reduced vimentin and phospho‐FAK levels in vivo. These findings indicated that oridonin can inhibit the migration and epithelial‐to‐mesenchymal transition (EMT) of SCLC cells by suppressing the FAK‐ERK1/2 signalling pathway. Thus, oridonin may be a new drug candidate to offer an effect of anti‐SCLC with relative safety.